1
|
Ferguson R, Archambault A, Simpson D, Kazlow E, Lax R, Moran U, Wilson M, Shapiro R, Pavlick A, Osman I, Polsky D, Kirchhoff T. Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Roy C, Lavoie M, Richard G, Archambault A, Lapointe J. Evidence that oxidative stress is higher in replacement gilts than in multiparous sows. J Anim Physiol Anim Nutr (Berl) 2016; 100:911-9. [PMID: 27079824 DOI: 10.1111/jpn.12462] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 12/05/2015] [Indexed: 11/28/2022]
Abstract
The recent success obtained in term of increasing the litter size of sows has not correlated with a reduction of replacement rate. There is thus an increased economic demand for gilts with optimal reproductive potential and longevity. Unfortunately, replacement gilts are known to be more susceptible to diseases and less productive than multiparous sows. Interestingly, reproductive performance, resistance to diseases and longevity could all be largely affected by oxidative stress. To investigate whether oxidative stress conditions could account for the poor longevity of gilts, three distinct groups of conventional Yorkshire × Landrace sows were formed based on their similar age and parity (gilts, second parity sows as well as fourth to fifth parity sows). All animals were slaughtered during the post-ovulatory period, and blood as well as tissue samples were collected. Biomarkers of oxidative damage to proteins (carbonyls) and DNA (8-OHdG) were analysed in samples. Specific mRNA expression of major antioxidants such as glutathione peroxidases 1, 3 and 4 (GPx1, GPx3, GPx4) as well as superoxide dismutases 1 and 2 (Sod1, Sod2) were monitored in liver and kidney samples by quantitative RT-PCR. Specific enzymatic activities of both GPx and SOD were measured by spectrophotometric assays. The plasma concentration of protein carbonyls was significantly different between the three groups with the highest concentration being observed in gilts (p ≤ 0.001). The mRNA expression levels of GPx1 and GPx4 were also significantly increased in the liver of gilts when compared to multiparous sows (p ≤ 0.05). SOD2 enzymatic activity was found to be higher in the liver of gilts than multiparous sows (p ≤ 0.05). Taken together, these results indicate that replacement gilts sustain significantly higher oxidative conditions than multiparous sows. Current findings may contribute to the design of nutritional regimens that will increase the productivity of gilts by counteracting oxidative stress.
Collapse
Affiliation(s)
- C Roy
- Dairy and Swine R & D Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada
| | - M Lavoie
- Dairy and Swine R & D Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada
| | - G Richard
- Dairy and Swine R & D Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada
| | - A Archambault
- Dairy and Swine R & D Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada
| | - J Lapointe
- Dairy and Swine R & D Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada.
| |
Collapse
|
3
|
Affiliation(s)
- J. Vargo
- Department of Accountancy, Finance and Information Systems, University of Canterbury, Private Bag 4800, Christ church, New Zealand
| | - J.C. Nesbit
- Information Technology and Interactive Arts Program, Simon Fraser University, 2400 Central City, 10153 King George Hwy, Surrey, BC, V3T 2W1, Canada;,
| | - K. Belfer
- Department of Accountancy, Finance and Information Systems, University of Canterbury, Private Bag 4800, Christ church, New Zealand
| | - A. Archambault
- Microsoft Corporation, 1 Microsoft Way, Redmond, WA 98052, USA
| |
Collapse
|
4
|
Vassant S, Archambault A, Marquier F, Pardo F, Gennser U, Cavanna A, Pelouard JL, Greffet JJ. Epsilon-near-zero mode for active optoelectronic devices. Phys Rev Lett 2012; 109:237401. [PMID: 23368264 DOI: 10.1103/physrevlett.109.237401] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Indexed: 06/01/2023]
Abstract
The electromagnetic modes of a GaAs quantum well between two AlGaAs barriers are studied. At the longitudinal optical phonon frequency, the system supports a phonon polariton mode confined in the thickness of the quantum well that we call epsilon-near-zero mode. This epsilon-near-zero mode can be resonantly excited through a grating resulting in a very large absorption localized in the single quantum well. We show that the reflectivity can be modulated by applying a voltage. This paves the way to a new class of active optoelectronic devices working in the midinfrared and far infrared at ambient temperature.
Collapse
Affiliation(s)
- S Vassant
- Laboratoire Charles Fabry, Institut d'Optique, CNRS, Université Paris-Sud, 2 avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
We present an explicit form of the surface plasmon propagator. Its form has the structure of a vectorial Huygens-Fresnel principle. The propagator appears to be a powerful tool to deal with diffraction, interference and focusing of surface plasmons. In contrast with the scalar approximation used so far, the vectorial propagator accounts for near-field and polarization effects. We illustrate the potential of the propagator by studying diffraction of surface plasmons by a slit and focusing of surface plasmons by a Fresnel lens.
Collapse
Affiliation(s)
- T V Teperik
- Laboratoire Charles Fabry de l'Institut d'Optique, CNRS and Université Paris-Sud, Campus Polytechnique, RD 128, 91127 Palaiseau cedex, France.
| | | | | | | |
Collapse
|
6
|
Triopon G, Tailland ML, Faillie JL, Bolzinger E, Mercier G, Ripart S, Boyer JC, Fabbro-Peray P, Poirey S, Archambault A, Marès P. Fécondation in vitro et tabac: intérêt de la cotininurie et de l'analyseur de monoxyde de carbone expiré. ACTA ACUST UNITED AC 2006; 34:1043-50. [PMID: 17070086 DOI: 10.1016/j.gyobfe.2006.09.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2006] [Accepted: 09/13/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To study the correlation between expired air carbon (EACO) and urinary cotinine, and to determine the impact of tobacco smoking on in vitro fertilization (IVF) results. PATIENTS AND METHODS We studied prospectively 221 patients in our ART center from October 2002 to October 2004: 51 active smokers, 85 passive smokers, and 85 non-smokers. Patients were classified into active, passive smokers, or non-smokers, based on a questionnaire. We measured urinary cotinine and EACO on the embryo transfer day and we recorded the IVF parameters. RESULTS Two hundred and twenty-one patients were included. We observed a 17.2% reduction of estradiolemy (P=0.05), a 1.5% reduction of pregnancies (NS), a 7.8% reduction of infants born alive (NS), a 28.5% reduction of twin pregnancies (P=0.06), as well as a 10% increase of miscarriages (NS) in the active smokers in comparison with non-smokers (the same trends were observed between active and passive smokers). EACO and urinary cotinine were well correlated. There was a negative correlation between estradiolemy and urinary cotinine (R=-0.15, P=0.02). DISCUSSION AND CONCLUSION Tobacco smoking intensity may be dilatory on IVF results. There is a high correlation between EACO and urinary cotinine. Other larger studies would probably obtain results more statistically significant.
Collapse
Affiliation(s)
- G Triopon
- Service de gynécologie-obstétrique, département de médecine de la reproduction, CHU Carémeau, place Robert-Debré, 30900 Nîmes cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005; 21:373-84. [PMID: 15709987 DOI: 10.1111/j.1365-2036.2005.02336.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
AIM To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease. METHODS Patients with corticosteroid-dependent Crohn's disease (use of prednisolone 15-40 mg/day or budesonide 9 mg/day for at least 8 weeks, a previous failed attempt to discontinue corticosteroids within 8 weeks, and Crohn's Disease Activity Index score 150 points or less) were enrolled in a 16-week, randomized, double-blind, placebo-controlled trial. The patients received intravenous CDP571 (20 mg/kg at week 0 and 10 mg/kg at week 8) or placebo. Corticosteroid therapy was decreased following a predefined schedule. The primary efficacy end-point was the percentage of patients with corticosteroid-sparing [i.e. no disease flare (Crohn's Disease Activity Index score > or =220 points) and no longer requiring corticosteroid therapy] at week 10. The major secondary efficacy end-point was corticosteroid-sparing at week 16. RESULTS Seventy-one patients received treatment. Corticosteroid-sparing was achieved by 19 of 39 (48.7%) CDP571 patients and 13 of 42 (40.6%) placebo patients (P = 0.452) at week 10, and by 18 of 39 (46.2%) CDP571 patients and seven of 32 (21.9%) placebo patients (P = 0.032) at week 16. CDP571 therapy was well-tolerated and the incidence of serious adverse events was similar to placebo. CONCLUSIONS The CDP571 was effective for corticosteroid-sparing at week 16 but not week 10, and was well-tolerated in patients with corticosteroid-dependent Crohn's disease.
Collapse
Affiliation(s)
- B G Feagan
- The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Lahaie R, Farley A, Dallaire C, Archambault A, Fallone CA, Ponich T, Hunt R, Oravec M, Whitsitt P, Van Zanten SV, Marcon N, Bailey R, Dumont A, Nguyen B, Desrochers S, Spénard J. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori. Can J Gastroenterol 2001; 15:581-5. [PMID: 11573100 DOI: 10.1155/2001/305756] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND A previous study showed that 14 days of qid bismuth-based triple therapy with tetracycline 500 mg, metronidazole 250 mg and colloidal bismuth subcitrate 120 mg resulted in excellent Helicobacter pylori eradication rates (89.5%). The present study looked at a shorter treatment period by adding omeprazole and by reducing the dose of tetracycline. METHODS One hundred sixty-one patients with H pylori confirmed by histology and (13)carbon urea breath test were included in the study. They were treated for seven days with bismuth subcitrate 120 mg plus metronidazole 250 mg plus tetracycline 250 mg qid plus omeprazole 20 mg bid (OBMT). Patients were 18 to 75 years of age and had dyspepsia with or without a history of peptic ulcer. Patients with irritable bowel syndrome, active ulcer or previous attempt at eradication, or those who had used antibiotics or antiulcer drugs in the previous 30 days were excluded. Eradication was determined by two (13)carbon urea breath tests done one and three months, respectively, after treatment. Strains with minimal inhibitory concentrations of 8 microg/mL or higher were considered to be resistant to metronidazole. RESULTS The overall per protocol eradication rate was 84%-89.5% in metronidazole-sensitive and 70.8% in metronidazole-resistant strains. Modified intent-to-treat analysis resulted in a 80% eradication rate--82.5% in metronidazole-sensitive and 66.7% in metronidazole-resistant strains. Only one patient discontinued treatment because of adverse events. CONCLUSIONS The OBMT regimen used in this study is safe and effective against metronidazole-sensitive H pylori strains.
Collapse
Affiliation(s)
- R Lahaie
- Centre Hospitalier de l'Université de Montréal, Hôpital St-Luc, 1058 St-Denis, Montréal, Quebec H2X 3J4, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-8. [PMID: 11313302 DOI: 10.1053/gast.2001.24042] [Citation(s) in RCA: 203] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND & AIMS We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the treatment of active Crohn's disease. METHODS One hundred sixty-nine patients with moderate-to-severe Crohn's disease were enrolled in a 24-week placebo-controlled trial. Patients were initially randomized to a single dose of 10 or 20 mg/kg CDP571 or placebo to assess dose response. Patients were then retreated with 10 mg/kg CDP571 or placebo every 8 or 12 weeks to assess subsequent dosing intervals. The primary endpoint was clinical response at week 2, defined as a decrease in the Crohn's Disease Activity Index score > or = 70 points. RESULTS At week 2, clinical response occurred in 45% of CDP571-treated patients compared with 27% of patients in the placebo group (P = 0.023). Patients appeared to benefit from retreatment with CDP571 over 24 weeks, but not all of the results for secondary endpoints were statistically significant. The frequency of severe or serious adverse events was similar among all groups. CONCLUSIONS CDP571 at an initial dose of 10 or 20 mg/kg is safe and effective for treatment of patients with moderate-to-severe Crohn's disease. Preliminary evidence suggests that retreatment with 10 mg/kg CDP571 at dose intervals of 8 or 12 weeks may also be beneficial, but additional studies are needed.
Collapse
|
10
|
McLemore ML, Grewal S, Liu F, Archambault A, Poursine-Laurent J, Haug J, Link DC. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 2001; 14:193-204. [PMID: 11239451 DOI: 10.1016/s1074-7613(01)00101-7] [Citation(s) in RCA: 155] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
To investigate the role of signal transducer and activator of transcription (STAT) proteins in granulocyte colony-stimulating factor (G-CSF)-regulated biological responses, we generated transgenic mice with a targeted mutation of their G-CSF receptor (termed d715F) that abolishes G-CSF-dependent STAT-3 activation and attenuates STAT-5 activation. Homozygous mutant mice are severely neutropenic with an accumulation of immature myeloid precursors in their bone marrow. G-CSF-induced proliferation and granulocytic differentiation of hematopoietic progenitors is severely impaired. Expression of a constitutively active form of STAT-3 in d715F progenitors nearly completely rescued these defects. Conversely, expression of a dominant-negative form of STAT-3 in wild-type progenitors results in impaired G-CSF-induced proliferation and differentiation. These data suggest that STAT-3 activation by the G-CSFR is critical for the transduction of normal proliferative signals and contributes to differentiative signals.
Collapse
Affiliation(s)
- M L McLemore
- Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Veldhuyzen Van Zanten S, Farley A, Marcon N, Lahaie R, Archambault A, Hunt R, Bailey R, Owen D, Spénard J, Stiglick A, Aimola N, Colin P. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study. Can J Gastroenterol 2000; 14:599-602. [PMID: 10978947 DOI: 10.1155/2000/690307] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To determine the rate of Helicobacter pylori eradication following bismuth-based triple therapy with colloidal bismuth subcitrate, tetracycline hydrochloride and metronidazole. PATIENTS AND METHODS One hundred and eleven patients were randomly assigned, in a two to one ratio, to colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid (Gastrostat), or matching placebo tablets and capsules for 14 days. Presence or absence of H pylori was documented by histology at entry and at least 28 days after treatment. Patients had dyspeptic symptoms with or without a history of peptic ulcer. Patients with any previous attempt(s) at eradication of H pylori, who used bismuth, antibiotics, H2 receptor antagonists or proton pump inhibitors in the previous four weeks were excluded. RESULTS Fifty-three of 59 (90%) patients on bismuth-based treatment and only one of 35 (3%) on placebo achieved eradication by per protocol analysis. Fifty-three of 65 (82%) patients on bismuth-based treatment achieved eradication, while only two of 34 (5%) achieved eradication on placebo by intention to treat analysis. Eradication rates for bismuth-based treatment across sites ranged from 83% to 100%. Only two patients in the bismuth-based treatment group (4%) and one in the placebo group (3%) discontinued treatment because of adverse events. CONCLUSIONS Colloidal bismuth subcitrate plus metronidazole plus tetracycline, given in the doses studied for 14 days, is safe and highly effective against H pylori infection and would be appropriate as a first-line therapy for eradication.
Collapse
|
12
|
Laurier C, Kennedy W, Malo JL, Par M, Labb D, Archambault A. Rate and cost of hospitalizations for asthma in Quebec: An analysis of 1988/89, 1989/90 and 1994/95 data. Chronic Dis Can 1999; 20:82-8. [PMID: 10455040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The objectives of this study were to evaluate recent trends in the frequency and length of stay of hospitalization for asthma in the province of Quebec and to estimate the costs of asthma hospitalizations. Data were extracted for persons hospitalized for 30 days or less with a primary diagnosis of asthma in all Quebec short-stay hospitals during the years 1988/89, 1989/90 and 1994/95. There were 1.76 asthma hospitalizations per 1000 persons in Quebec in 1988/89, down to 1.44 in 1989/90 and up again to 1.75 in 1994/95. There was a small decrease in mean length of stay when the three data years were compared. In all three years, the rate of hospitalization was particularly high among young boys. In 1994/95, more hospitalizations occurred during the fall months. We estimated the total cost for asthma hospitalization that year to be $18 to $21 million.
Collapse
Affiliation(s)
- C Laurier
- Faculté de pharmacie, Université de Montréal, Montreal, Quebec, H3C 3J7, Canada
| | | | | | | | | | | |
Collapse
|
13
|
Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, Fedorak R, Bazzoli F, Hentschel E, Mora P, Archimandritis A, Megraud F. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997; 11:943-52. [PMID: 9354205 DOI: 10.1046/j.1365-2036.1997.00223.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Whilst the role of Helicobacter pylori eradication in managing duodenal ulcers has been established, consensus regarding the ideal regimen has not been achieved. METHODS Patients with H. pylori-positive active duodenal ulcer were randomly assigned to receive triple therapy with amoxycillin 1000 mg b.d. + clarithromycin 500 mg b.d. + omeprazole 20 mg daily for 10 days (ACT-10) or dual therapy with clarithromycin 500 mg t.d.s. + omeprazole 40 mg daily for 14 days (Dual). No additional acid suppression was provided following eradication therapy. Endoscopy, with biopsy for culture and histology, as well as 13C-urea breath testing (13C-UBT) were performed pre-treatment to assess H. pylori infection. H. pylori eradication was established at 4-6 weeks follow-up with culture (2 antral, 1 corpus biopsies), histology (2 antral biopsies), and 13C-UBT. Ulcer healing by endoscopy and change in clinical symptoms were also assessed at 4-6 weeks. RESULTS Two hundred and sixty-seven (267) patients were randomized to ACT-10 (n = 137) or Dual therapy (n = 130). By per-protocol and intention-to-treat analyses, H. pylori eradication at 4-6 weeks follow-up was 91% (115/127) and 88% (120/136), respectively, for ACT-10 patients and 59% (68/115) and 55% (72/130), respectively, for Dual therapy patients (P < 0.001 for both analyses). Ulcer healing was high in both treatment groups: ACT-10, 93% (118/127) and 90% (122/136), respectively; and Dual therapy, 91% (104/114) and 85% (111/130), respectively. Pre-treatment resistance to clarithromycin was low (4%, 8/214) as compared to metronidazole resistance which was over 40%. Emergence of resistance to clarithromycin was observed in 2% of patients receiving ACT-10 and in 25% of those receiving Dual therapy. ACT-10 and Dual therapy patients experienced similar rates of drug-related adverse events (33% vs. 32%, respectively) and discontinuation from therapy due to an adverse event (1.5% vs. 5%, respectively). More than 90% of patients were compliant with each prescribed medication. CONCLUSION In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H. pylori and healing duodenal ulcer.
Collapse
Affiliation(s)
- H Wurzer
- Department of Gastroenterology, Landeskrankenhaus-Universitaetskliniken, Graz, Austria
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Champion MC, MacCannell KL, Thomson AB, Tanton R, Eberhard S, Sullivan SN, Archambault A. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997; 11:127-34. [PMID: 9113812 DOI: 10.1155/1997/314839] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Cisapride is a substituted benzamide with gastrointestinal prokinetic effects presumed to be due to the enhancement of the physiological release of acetylcholine at the myenteric plexus. In a multicentre study, 189 patients with nonulcer dyspepsia (NUD) received single-blind placebo treatment for two weeks. A total of 123 patients with no or minimal response to placebo and epigastric pain of at least moderate severity and frequency were randomly assigned to one of the three parallel double-blind treatments for six weeks: cisapride 10 mg tid, cisapride 20 mg tid or placebo. The severity and frequency of individual symptoms (epigastric pain, heartburn, nausea, vomiting anorexia, postprandial discomfort, regurgitation, lower abdominal pain, bloating and constipation) were assessed on a four- and five-point categorical scale, respectively, by the investigator at three on treatment visits and by patients in a daily diary. Analysis of investigator and patient assessments for differences in symptom severity x frequency composite scores among the three treatment groups showed no statistically significant differences for individual symptoms or symptom clusters. As assessed by the investigator, and compared with baseline, cisapride 20 mg tid significantly (P < 0.05) improved epigastric pain, bloating and early satiety as well as improved the total symptom cluster. Investigator evaluation of the five most severe and frequent symptoms for each patient showed statistically significant improvement in each treatment group. For patient diary assessments, statistically significant within-treatment improvement of the total symptom cluster, the five most severe symptoms cluster, bloating and early satiety was observed for both cisapride 20 mg and placebo, whereas epigastric pain significantly (P < 0.05) improved in all three treatment groups. Investigator evaluation of global response (good+excellent) rate at the end of the six week treatment period was 38% for cisapride 20 mg, 47% for cisapride 10 mg and 33% for placebo. No statistically significant difference in this parameter among treatments was noted. Cisapride was well tolerated at both doses with a side effect profile comparable with that of placebo. It is concluded that in this double-blind multicentre study with a single-blind two-week placebo run in phase, cisapride 10 mg tid and 20 mg tid were not effective compared with placebo in improving symptoms in NUD patients. This study re-emphasizes the good prognosis of patients with NUD, with 14% of patients improving in the two-week placebo run-in phase and a further 33% improving in the next six weeks while on placebo. Within-treatment analysis of investigator assessments showed improvement for cisapride 20 mg tid suggesting a trend of efficacy at this dose.
Collapse
Affiliation(s)
- M C Champion
- Ottawa Civic Hospital, University of Ottawa, Ontario
| | | | | | | | | | | | | |
Collapse
|
15
|
Laurier C, Kennedy W, Gariépy L, Archambault A, Contandriopoulos AP. Utilization of anti-asthma medications in two Quebec populations of anti-asthma medication users: a prescription database analysis. Chronic Dis Can 1997; 18:20-6. [PMID: 9188516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study describes the utilization of anti-asthma medications in two groups of users of such medications in the province of Quebec, Canada, during the year from June 1, 1990, to May 31, 1991. It is based on a secondary analysis of existing data banks recording the medications reimbursed by two government-funded ambulatory drug reimbursement programs that cover individuals aged 65 and over (seniors) and income security (welfare) recipients (ISRs). The study analyzed the use of the anti-asthma medications included in the list of medications eligible for reimbursement for program beneficiaries. Use was studied in two random samples of individuals who had at least one prescription filled for an anti-asthma medication (2566 seniors and 3695 ISRs). The most commonly used medication in both groups was inhaled salbutamol 100 mcg. Various forms of theophylline tablets were also used by a high proportion of the sample studied. Over 75% of the seniors and 68% of the ISR group used at least one form of theophylline during the course of the year. Inhaled corticosteroids were used by 43% of the seniors and by 36% of the ISR group, and sympathomimetics (beta 2-agonists), by 63% of seniors and 68% of ISRs.
Collapse
Affiliation(s)
- C Laurier
- Faculté de pharmacie, Université de Montréal, Centre-ville, Québec
| | | | | | | | | |
Collapse
|
16
|
Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330:1846-51. [PMID: 8196727 DOI: 10.1056/nejm199406303302602] [Citation(s) in RCA: 170] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Long-term corticosteroid therapy for Crohn's disease is associated with important types of morbidity, such as osteoporosis. Safe and effective alternative treatments are required. Although a short-term benefit of cyclosporine in active Crohn's disease has been suggested, the long-term safety and efficacy of this treatment have not been established. METHODS We conducted a randomized, double-blind, placebo-controlled evaluation of the effect of 18 months of low-dose cyclosporine treatment on the course of Crohn's disease. Adult patients whose disease had been active within the previous two years were randomly assigned to receive cyclosporine (151 patients) or placebo (154 patients) in addition to their usual therapy. Randomization was stratified according to center and score on the Crohn's Disease Activity Index (193 patients had scores of 150 or less, and 112 had scores greater than 150). The primary outcome measure was clinically important worsening of Crohn's disease, defined as a 100-point increase in the Crohn's Disease Activity Index from the patient's base-line value. Secondary outcomes were the use of prednisone and 5-amino-salicylates, mean score on the Crohn's Disease Activity Index and mean quality-of-life score, and the need for surgery. RESULTS The condition of more patients worsened with cyclosporine than with placebo (91 of 151, or 60.3 percent, vs. 80 of 154, or 51.9 percent; P = 0.10). The median time to worsening of disease in patients receiving cyclosporine was 338 days, as compared with 492 days in patients receiving placebo (P = 0.25; relative risk, 1.22; 95 percent confidence interval, 0.86 to 1.72). Analyses of the mean Crohn's Disease Activity Index and quality-of-life scores and of the use of prednisone and 5-aminosalicylates also failed to demonstrate benefit. CONCLUSIONS In our patient population, the addition of low-dose cyclosporine to conventional treatment for Crohn's disease did not improve symptoms or reduce requirements for other forms of therapy.
Collapse
Affiliation(s)
- B G Feagan
- Department of Medicine, University of Alberta, Edmonton, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106:287-96. [PMID: 8299896 DOI: 10.1016/0016-5085(94)90585-1] [Citation(s) in RCA: 483] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND/AIMS Quality of life (QOL), a subjective index of health perception and function, embraces physical, social, and emotional performance but has not had a prominent role in clinical trials of inflammatory bowel disease (IBD). To test the robustness of the Inflammatory Bowel Disease Questionnaire (IBDQ), a disease-specific QOL index, this study assessed its validity, reliability, and responsiveness during a multicenter trial. METHODS Three hundred five patients with stable Crohn's disease received cyclosporin or placebo for 18 months. IBDQ and dimensional scores (bowel, social, systemic, and emotional) were correlated with disease activity (Crohn's disease activity index [CDAI] and Harvey-Bradshaw index). Concordance of IBDQ scores was tested in 280 stable subjects. Linear regression evaluated change in IBDQ scores over time. RESULTS IBDQ scores correlated highly with CDAI (r = -0.67; P < 0.0001). The reliability coefficient for IBDQ score was 0.70 vs. 0.66 for CDAI and 0.55 for Harvey-Bradshaw index. Regression line slopes of IBDQ scores were significantly different in patients who deteriorated from those who remained stable ([b] < 0.15; P < 0.0001). QOL scores were lower in patients who required surgery. CONCLUSIONS The IBDQ is a valid reliable assessment tool that reflects important changes in the health status of patients with IBD. The IBDQ is a robust measure of therapeutic efficacy and should be used in future clinical trials in IBD.
Collapse
Affiliation(s)
- E J Irvine
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Grégoire JP, Guibert R, Archambault A, Contandriopoulos AP. Medication Compliance in a Family Practice: Testimg a self-report questionnaire in a primary care setting. Can Fam Physician 1992; 38:2333-2337. [PMID: 21221293 PMCID: PMC2145563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
For the physician in a primary care setting, a self-report questionnaire on medication compliance can help to determine whether a lack of hypertension control is due to a drug-taking behavior problem or inadequate medication. Such a questionnaire can easily be implemented as a part of routine care and can help clinicians increase the efficiency of medical care dispensed to hypertensive patients.
Collapse
|
19
|
Perrault L, Beauchamp G, Bastien E, Laurendeau F, Jobin G, Archambault A. Surgical treatment of achalasia in a general hospital. Can J Surg 1991; 34:487-90. [PMID: 1913396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The authors report their experience with 43 patients treated for achalasia of the esophagus in a general hospital between 1971 and 1986. Patients were divided into two groups according to the type of surgery performed: group 1--29 patients treated by Heller myotomy, performed by nine general surgeons between 1971 and 1983; and group 2--14 patients treated by transthoracic Heller myotomy with the addition of a Belsey Mark-IV fundoplication. Dysphagia was reduced postoperatively in 82.6% of patients in group 1 and 92.8% of patients in group 2. Three patients in group 1 and one patient in group 2 had persistent dysphagia. Ten patients in group 1 had symptoms of gastroesophageal reflux (5 of them required a second antireflux procedure). In group 2, one patient had symptoms of gastroesophageal reflux, but was treated successfully medically. There was no difference in the degree of relief of dysphagia between the abdominal and thoracic approach, or in whether the operation was performed by a general surgeon without specific experience in the treatment of achalasia. The addition of a fundoplication to a Heller myotomy appeared to lessen the problem of postoperative gastroesophageal reflux. Since the Heller myotomy is technically difficult and may lead to obstruction of the poorly emptying esophagus the authors recommend that it be used selectively and only by the experienced esophageal surgeon.
Collapse
Affiliation(s)
- L Perrault
- Division of General Surgery, Hôpital Maisonneuve-Rosemont, Montreal, Que
| | | | | | | | | | | |
Collapse
|
20
|
Archambault A. Ulcerative colitis: an overview. Can Fam Physician 1990; 36:343-351. [PMID: 21234051 PMCID: PMC2280645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Idiopathic ulcerative colitis primarily affects young adults. Colonic symptoms are the most annoying. In severe colitis, systemic and extraintestinal inflammatory manifestations can be disabling. Proximal extension of colitis is demonstrated by double-contrast barium enema and total colonoscopy. Bacterial and parasitic colitis must be excluded by appropriate microbiological studies. Colonoscopy is recommended to screen for high-grade dysplasia or neoplasia in cases of chronic diffuse colitis (after seven years). Severe colitis can benefit from hospitalization, parenteral nutritional support, and high doses of corticosteroids that are progressively tapered. Mild or moderate cases or severe cases in remission respond well to rest, low-irritant diets, mild symptomatic medication, oral sulfasalazine, or more recent 5-acetylsalicylic derivatives. Long-term maintenance with reduced dosages will control more than 80% of cases.
Collapse
|
21
|
Abstract
Communication of verbal information on prescribed drugs is recognized as an important function of the pharmacist. This article describes and analyzes the communication behavior adopted by community pharmacists in the province of Quebec. Data were collected by means of two questionnaires mailed to a random sample of 634 community pharmacists. Percentage of prescriptions for new medications on which the pharmacists indicated they provide verbal information averaged 68.9 (SD 24.2). A majority of respondents indicated that they include information on the indication and mode of administration in more than 75 percent of their counseling episodes. However, on average, rare but serious adverse effects were less frequently discussed. The frequency of verbal communication was analyzed according to the pharmacist's gender, number of years since licensure, employment status, work setting, and perceptions of both professional and commercial dimensions of the pharmacist's role. Regression showed that perception of the professional dimension of the role, gender, workload, and floor surface of the pharmacy were related to provision of verbal information on new prescribed medications.
Collapse
Affiliation(s)
- C Laurier
- School of Pharmacy, Université Laval, Cité Universitaire, Québec, Canada
| | | | | |
Collapse
|
22
|
Archambault A. Cost-effectiveness in healthcare: complexity of the equation. J Can Diet Assoc 1989; 49:80-5. [PMID: 10312528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Integrating scientific changes, citizens' needs and economic constraints has become a challenge. New types of cost-effective services, technologies and products must be found. Manufacturers, hospital administrators and health professionals must be capable of effectively documenting the benefits, risks and costs of their services to society and the quality of care to patients. Choices must be made to decide upon appropriate actions in allocating and using resources. The concepts of cost-benefit analysis and cost-effectiveness analysis should be understood. Identifying and valuing costs and benefits, measuring effectiveness, and assessing quality of life are complex and difficult issues. They are discussed in reference to Canadian studies on the cost-effectiveness of nutrition support. The need for further research to improve cost-effectiveness of nutrition support is stressed.
Collapse
|
23
|
Aumais G, Chatti N, Jobin G, Archambault A. [Pancreas divisum: retrospective study of 980 retrograde catheterizations of the papilla]. Union Med Can 1986; 115:382-6. [PMID: 3739054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
24
|
Farley A, Lévesque D, Paré P, Thomson AB, Sherbaniuk R, Archambault A, Mahoney K. A comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcer. Am J Gastroenterol 1985; 80:665-8. [PMID: 3898818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A multicenter double-blind comparative trial of oral ranitidine, 300 mg hs versus 150 mg bid, was conducted in 89 patients with duodenal ulcer (DU) and 54 with gastric ulcer (GU). Antacid tablets were prescribed prn. After 4 wk of treatment there were no statistically significant differences in the ulcer healing rates associated with the once daily (DU 86.4%, GU 62.5%) and the twice daily (DU 84.4%, GU 73.3%) regimens. Antacid consumption, by both DU and GU patients, was higher in the 150 mg bid group, but the differences did not achieve statistical significance. Further improvement in cumulative healing rates in response to both treatment regimens was observed following a second 4-wk treatment for those patients whose ulcers had failed to heal during the 1st month. Smoking adversely affected the rate of ulcer healing in DU patients, but had no significant effect on GU healing. No serious adverse effects or biochemical abnormalities were observed. Ranitidine 300 mg hs appears to be equally safe and effective as the standard regimen of 150 mg bid in the short-term treatment of uncomplicated gastroduodenal ulcer.
Collapse
|
25
|
Archambault A. [H2 receptor antagonists: clinical use]. Union Med Can 1984; 113:990-1, 995-8, 1023. [PMID: 6151278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
26
|
Sontag S, Graham DY, Belsito A, Weiss J, Farley A, Grunt R, Cohen N, Kinnear D, Davis W, Archambault A. Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med 1984; 311:689-93. [PMID: 6382004 DOI: 10.1056/nejm198409133111101] [Citation(s) in RCA: 168] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Three hundred seventy patients with recently healed duodenal ulcer entered into a one-year, double-blind, randomized multicenter trial comparing placebo with three different dose schedules of cimetidine (200 mg twice a day, 300 mg twice a day, and 400 mg at bedtime) for the prevention of recurrent duodenal ulcer. By the end of one year, the cumulative symptomatic recurrence rate as demonstrated by endoscopy was similar for the patients receiving the three dosages of cimetidine (19 per cent, 15 per cent, and 13 per cent, respectively; not significant), whereas the placebo-treated group had a 34.7 per cent symptomatic recurrence rate (P less than 0.01 as compared with each cimetidine group). Cigarette smoking was found to be an important variable; among the placebo recipients ulcer recurrence was significantly more likely in smokers (72 per cent) than in nonsmokers (21 per cent, P less than 0.001). The frequency of ulcer recurrence in smokers was significantly reduced by treatment with cimetidine (from 72 per cent to 34 per cent, P less than 0.). Smokers who received cimetidine were at least as likely to have a recurrence as were nonsmokers who received placebo (34 per cent vs. 21 per cent, not significant). Thus, smoking appears to be a major factor in recurrence of duodenal ulcer, and in smokers, giving up smoking may be more important in the prevention of ulcer recurrences than administration of cimetidine.
Collapse
|
27
|
|
28
|
Leroux P, Farley A, Archambault A, Pilon G, Gosselin D, Paré P, Lévesque D, Sherbaniuk R, Thomson AB. Effect of ranitidine on healing of peptic ulcer: a 2-month study. Am J Gastroenterol 1983; 78:227-30. [PMID: 6301262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A multicenter trial of oral ranitidine 150 mg bid was conducted in 41 patients with duodenal and 30 with gastric ulcers. Patients were randomly allocated in double-blind fashion to 4 wk treatment with either ranitidine or placebo, after which all unhealed patients were given 4 wk on the active drug without breaking the original allocation code. After 4 wk of treatment the healing rate associated with ranitidine was significantly superior to that of placebo in both duodenal and gastric ulcer patients. Further improvement in cumulative healing rates was observed after the 2nd month of the study. After the allocation code was broken and all patients had had the opportunity of up to 8 wk on the active drug, there remained only a single unhealed pyloric ulcer. No serious adverse effects or biochemical abnormalities were observed. Ranitidine is a potent and well-tolerated H2 antagonist. Therapy for 4 or 8 wk is highly effective in the treatment of uncomplicated gastroduodenal ulcer.
Collapse
|
29
|
Ford-Jones L, Clogg D, Delage G, Archambault A. Health spa whirlpools: a source of Pseudomonas folliculitis. Can Med Assoc J 1981; 125:1005-6. [PMID: 7332886 PMCID: PMC1862502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
30
|
Beauchamp G, Beliveau D, Archambault A. Death and complications after total colectomy for inflammatory bowel disease. Can J Surg 1981; 24:463-6, 484. [PMID: 7284908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Deaths and complications related to proctocolectomy in inflammatory bowel disease remain a serious problem for the general surgeon. Review of experience at a general hospital over a 25-year period disclosed that although there was substantial morbidity and 12.5% mortality there was a notable improvement over the last 10 years of the study. This was due mainly to a more aggressive surgical approach, meticulous preparation of the bowel for elective procedures, more physiologic monitoring peroperatively, careful replacement of fluid losses and intensive care postoperatively. Many patients with septic and nonseptic complications required reoperation. Intestinal occlusion by adhesions and ileostomy dysfunction are the most common nonseptic complications. One-stage proctocolectomy is a good choice for elective surgery but should be used with caution in emergency situations.
Collapse
|
31
|
|
32
|
Gambert P, Lallemant C, Archambault A, Maume BF, Padieu P. Assessment of serum cholesterol by two methods: gas-liquid chromatography on a capillary column and chemical ionization-mass fragmentography with isotopic dilution of [3,4-13C] cholesterol as internal standard. J Chromatogr 1979; 162:1-6. [PMID: 368084 DOI: 10.1016/s0378-4347(00)82057-5] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A gas-liquid chromatographic (GLC) method and an isotopic dilution-mass fragmentographic (ID-MF) procedure using the same capillary chromatographic separation are described for serum cholesterol assay. GLC included silylation and separation on a highly efficient glass capillary column which allowed the separation of cholesterol from cholestanol and the use of epicoprostanol as internal standard. The concentrations were calculated from the areas of the signals and digitalized by a reporting integrator. The reproducibility was 0.5% and the correlation with the ID-MF technique was 0.997. The ID-MF technique was characterized by the use of [3,4-13C] cholesterol as the labelled standard and a chemical ionization mode. The reproducibility was 0.8%.
Collapse
|
33
|
Abstract
An HF generator based on the dissociation pressure of an alkali bifluoride is described. Sodium bifluoride salt was found to yield HF pressures of the order of 0.001 to 0.3 mm in the temperature range 60 to 135 °C due to the equilibrium [Formula: see text]. The HF generator allows a dry carrier gas (typically N2) to pass through a thermoregulated chamber filled with the crystalline bifluoride and furnishes HF concentrations from 5 to 1000 ppm at flowrates up to 5 ℓ/min for periods up to one year. The HF concentrations thus generated were stable to within 1% after a 40 min warm up period. Described also is the associated control system which allows the operator to send alternately dry carrier gas with or without trace HF concentration to an external cell or analyser.
Collapse
|
34
|
Gillies RR, Archambault A, Kinnear DG, Lacerte M. Controlled comparison of two dosage regimens of cimetidine in duodenal ulcer: a multicenter study. Gastroenterology 1978; 74:396. [PMID: 340328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
35
|
Archambault A, Farley A, Gosselin D, Martin F, Birkett JP. Evaluation of Duogastrome (carbenoxolone sodium) for the treatment of duodenal ulcer: a multicentre study. Can Med Assoc J 1977; 117:1155-9. [PMID: 603844 PMCID: PMC1880270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A double-blind study was carried out in 152 Canadian patients, 76 given Duogastrone (carbenoxolone sodium) capsules, 50 mg qid, and 76 given placebo capsules qid for 6 weeks. All patients had a duodenal ulcer diagnosed by roentgenography or endoscopy, or both. Evaluation of the efficacy of Duogastrone therapy was based on data from the 119 patients (59 treated with Duogastrone and 60 with placebo) who met all the strict requirements of the protocol. The ulcers healed completely in 75% (44/59) of the patients treated with Duogastrone and in 48% (29/60) of those treated with placebo; this difference is significant (P less than 0.01). The proportions were similar in the patients assessed only endoscopically: 76% (32/42) and 55% (26/47), respectively. In the group treated with Duogastrone the following side effects were noted: weight gain, edema, mild hypokalemia, increase in blood pressure and slight increases in serum concentrations of lactic dehydrogenase and alkaline phosphatase. None was serious. However, close clinical monitoring by weekly visits to their physician is recommended for every patient undergoing Duogastrone therapy, at least during the 1st month.
Collapse
|
36
|
Giroux Y, Archambault A, Farley A, Gosselin D, Orr JM, Marier G, Schipper HL. [Effects on the gastric mucosa of coated acetylsalicylic acid (Entrophen) and ordinary acetylsalicylic acid: comparative study by endoscopy]. Union Med Can 1977; 106:841-7. [PMID: 883049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
37
|
Archambault A, Bourgie J, Lamoureux C. [Evaluation of colonic diseases: colonoscopy and radiology]. Union Med Can 1977; 106:853-61. [PMID: 883050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
38
|
Farley A, Lévesque D, Archambault A, Gagnon M, Giroux Y, Gosselin D, Martin F, Lafrance R, Morgan SR, Tassé D, Bernard D. [The Mallory-Weiss syndrome: apropos of 68 cases encountered among 603 cases of digestive hemorrhage at the Hôpital Saint-Luc and the Centre de Gastro-Entérologie de Montréal]. Union Med Can 1977; 106:652-6. [PMID: 867602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
39
|
Abstract
The difficulties encountered in the diagnosis of solitary pancreatic injury when there is no other indication for surgical exploration of the abdomen are discussed. We suggest that endoscopic transduodenal pancreatography is a reliable diagnostic tool of great help in evaluating such injuries with little morbidity.
Collapse
|
40
|
Giroux Y, Archambault A, Farley A. [Indications and contraindications of endoscopic cholangio-pancreatography]. Union Med Can 1976; 105:62-4. [PMID: 1246752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
41
|
Archambault A, Giroux Y, Farley A, Bourgie J, Bessette G, Mheir H. [Endoscopic catheterization of Vater's papilla]. Union Med Can 1976; 105:61-2. [PMID: 1246751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
42
|
Archambault A, Giroux Y, Farley A. [Endoscopic cholangic-pancreatography: methodological and endoscopic aspect]. Union Med Can 1976; 105:64-7. [PMID: 1246753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
43
|
Archambault A, Giroux Y, Bourgie J, Bessette G. [Initial success and diagnostic value of endoscopic cholangio-pancreatography at Maisonneuve-Rosemont Hospital]. Union Med Can 1976; 105:76-83. [PMID: 1246755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
44
|
Giroux Y, Bessette G, Archambault A. [The pentagastrin test: clinical correlations of 400 patients]. Union Med Can 1975; 104:1801-11. [PMID: 1216376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
45
|
Laplante L, Mousseau R, Beaudry C, Thibert F, Archambault A. [Pentagastrine test in chronic renal insufficiency (study of 50 cases)]. Union Med Can 1973; 102:2497-501. [PMID: 4543948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
46
|
Archambault A, Thibert F. [Stomach chemistry: interpretation of the pengastrine test]. Union Med Can 1973; 102:2501-3. [PMID: 4772548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
47
|
Laplante L, Archambault A, Thibert F. [The carcinoid syndrome]. Union Med Can 1971; 100:1970-84. [PMID: 5316830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
48
|
Archambault A, Palaic D, Perras P, Lamarche J, Laplante L, Laurendeau F, Proulx J, Thibert F. [Carcinoid syndrome. Presentation of a clinical case]. Union Med Can 1971; 100:1961-9. [PMID: 5142214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
49
|
Archambault A, Darbari DM, Thibert F. [Maximum histamine stimulation test: reevaluation]. Union Med Can 1970; 99:1227-1233. [PMID: 5508275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
50
|
Delorme J, Archambault A. [pH in situ during maximal histamine test]. Union Med Can 1970; 99:258-63. [PMID: 5415535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|